All In Biotech

NDA 212157 · Scilex Pharms

Elyxyb

Celecoxib · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

May 5, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

631

125 Phase 3, 38 recruiting

FAERS reports

35,685

26,846 serious, 6,053 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS WARNING: RISK OF SERIOUS CARDIOVASCULAR and GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. ( 5.1 ) ELYXYB is contraindicated in the setting of coronary artery bypass graft (CABG) surgery. ( 4 , 5.1 ) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease...

What it is approved for

From the label in effect Nov 26, 2024.

ELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. ELYXYB is a nonsteroidal anti-inflammatory drug indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. ( 1 )

Mechanism: Celecoxib is a nonsteroidal anti-inflammatory drug with analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action by which celecoxib exerts therapeutic effects in migraine patients is not fully understood but may involve inhibition of prostaglandin synthesis, primarily via inhibition of COX-2.

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ELYXYB · CELECOXIB 25MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Celecoxib" as an intervention, any sponsor and status, largest first.

All 631 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,458
  • off label use3,498
  • fatigue3,409
  • arthralgia3,339
  • pain3,325
  • nausea3,299
  • diarrhoea2,965
  • vomiting2,687
  • rheumatoid arthritis2,594
  • rash2,565
  • headache2,487
  • condition aggravated2,434

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004857
2005679
2006215
2007349
2008556
2009465
2010444
2011658
2012544
2013465
2014450
20151,302
20161,642
20171,740
20181,918
20192,365
20202,679
20212,689
20223,027
20232,739
20243,358
20254,089
20262,455

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Elyxyb (Celecoxib)

2024 spending

$1.7M

Beneficiaries

479

1,462 claims

Per beneficiary

$3,576

$29.54 per unit

View as table
YearSpending
2020$0
2021$0
2022$290,447
2023$603,807
2024$1,713,050

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,234 on PubMed

Sponsor: Scilex Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.